Anthracyclines are a specific class of medications for adjuvant chemotherapy. They disrupt the enzymes (proteins that help chemical reactions in cells) that copy DNA during a cell’s life.

For decades, anthracyclines have been the gold standard of treatment for women with breast cancer, but that could be changing. Ever since Dennis J. Slamon, MD, director of clinical/translational ...

A retrospective analysis of four phase II trials and one phase III trial evaluated the prognostic impact of adjuvant anthracyclines on the efficacy of first-line epirubicin–paclitaxel regimens ...

"Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease," she concluded.

SAN ANTONIO — The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer, according to data presented at San Antonio ...

December 18, 2006 (San Antonio) — Anthracyclines have formed the backbone of adjuvant treatment for breast cancer, but new data presented at the 29th Annual San Antonio Breast Cancer (SABC ...

Additionally, the benefits of anthracyclines in lower-risk patients (RS 26–30) may have been difficult to measure because of the overall lower risk of recurrence in this population.

Anthracyclines disrupt tumor growth by binding to and blocking the function of topoisomerase II (TOP2). Topoisomerases break, twist, and reseal the phosphate backbone of DNA and, in so doing ...

The long-term results did not make a compelling case for continued use of anthracyclines as adjuvant breast cancer therapy, according to the authors of an accompanying editorial. "A persistent ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Among people receiving chemotherapy regimens containing anthracyclines for lymphoma, those who took the cholesterol-lowering drug atorvastatin for one year were significantly less likely to show ...

"Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease," she concluded.